Vertex Pharmaceuticals Inc.
Income Statement
| Line Item | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 |
|---|---|---|---|---|---|
| Revenue | $143.2M | $101.9M | $175.5M | $213.9M | $161.7M |
| Net Product Revenues | $0 | — | — | $0 | $0 |
| Collaborative and Royalty Revenues | $143.2M | — | — | $213.9M | $161.7M |
| Cost of Revenue | $0 | — | — | — | — |
| Gross Profit | $143.2M | — | — | — | — |
| Gross Margin | 100.0% | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $637.4M | $550.3M | $516.9M | — | — |
| SG&A Expense | $187.8M | $130.2M | $101.3M | — | — |
| Operating Income | $-696.1M | $-614.0M | $-462.7M | — | — |
| Operating Margin | -486.2% | -602.6% | -263.6% | — | — |
| Interest Expense | $19.3M | $13.2M | $13.5M | — | — |
| Pretax Income | $-754.6M | $-642.2M | $-459.9M | — | — |
| Income Tax Expense | $0 | — | — | — | — |
| Net Income | $-754.6M | $-642.2M | $-459.9M | — | — |
| Net Margin | -527.0% | -630.3% | -262.0% | — | — |
| EPS (Basic) | $-3.77 | $-3.71 | $-3.27 | — | — |
| EPS (Diluted) | $-3.77 | $-3.71 | $-3.27 | — | — |
| Shares Outstanding (Basic) | 200.4M | 173.3M | 140.6M | — | — |
| Shares Outstanding (Diluted) | 200.4M | 173.3M | 140.6M | — | — |
| Dividends Per Share | — | — | — | — | — |